Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU

Why It Matters

The approval offers the first targeted therapy for relapsed or refractory BRAF‑altered pLGG, addressing a critical unmet need and potentially reshaping treatment standards in Europe.

Key Takeaways

• Ojemda gets EU conditional approval for BRAF-altered pediatric LGG
• Approval covers patients ≥6 months after at least one prior therapy
• FIREFLY-1 trial showed 71% ORR by RANO-HGG criteria
• Median duration of response reached 18 months in responders

Pulse Analysis

Pediatric low‑grade glioma, while generally indolent, can become aggressive when standard chemotherapy fails, especially in children harboring BRAF alterations. Historically, treatment options have been limited to surgery, radiation, and non‑specific chemotherapy, each carrying significant long‑term toxicity. Ojemda, a selective pan‑RAF inhibitor, targets the MAPK pathway directly, offering a mechanistic advantage that aligns with the molecular drivers of these tumors. Its oral formulation also simplifies administration for young patients and caregivers, a notable benefit over intravenous regimens.

The FIREFLY‑1 trial enrolled 137 patients aged six months to 25 years across two arms, providing robust efficacy data for a rare pediatric indication. An overall response rate of 71% by RANO‑HGG criteria—and 53% by the more stringent RAPNO‑LGG criteria—demonstrates meaningful tumor shrinkage. Clinical benefit rates of 77% and 58% further underscore durable disease control. Responders achieved a median time to response of just over five months, and the median duration of response extended to 18 months, suggesting sustained benefit in a population with limited alternatives. Safety signals were manageable, supporting the conditional approval despite the trial’s relatively small size.

For Ipsen, the conditional EU approval marks a strategic milestone, positioning the company as a leader in pediatric oncology targeted therapies. The decision also signals regulatory openness to conditional pathways for high‑unmet‑need indications, potentially accelerating future submissions in the United States and other markets. Competitors will now need to demonstrate comparable efficacy or differentiated safety to challenge Ojemda’s emerging market share, while payers will scrutinize cost‑effectiveness given the therapy’s novel status. Overall, the approval could catalyze further investment in BRAF‑directed treatments across pediatric neuro‑oncology.